Since biomarkers proposed to date, such as fMRI signal fluctuations [4–6], inflammatory cytokines [7, 8] or BDNF [9–11], are not directly associated with synaptic dysfunction, TMS-based biomarkers allow us to proxy a so far unrepresented aspect of MDD. This evidence concerns the gene BDNF and major depressive disorder.